Skip to content
10-Q

Quarterly Report

Lyell Immunopharma, Inc. LYEL

0001628280-26-031284

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 23.33M sh
Shares Diluted Q1 2026 · Mar 31, 2026 21.88M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 14.76M sh
Capex Q1 2026 · Mar 31, 2026 $89K
Capex Q1 2026 · Mar 31, 2025 $246K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$38.51M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$54.74M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $90.77M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $60.18M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $120.33M
Stockholders Equity Q1 2026 · Mar 31, 2026 $273.67M
Stockholders Equity Q1 2026 · Dec 31, 2025 $248.2M
Stockholders Equity Q1 2026 · Mar 31, 2025 $336.52M
Stockholders Equity Q1 2026 · Dec 31, 2024 $382.82M
Current Liabilities Q1 2026 · Mar 31, 2026 $36.95M
Current Liabilities Q1 2026 · Dec 31, 2025 $49.41M
Total Liabilities Q1 2026 · Mar 31, 2026 $76.96M
Total Liabilities Q1 2026 · Dec 31, 2025 $91.85M
Current Assets Q1 2026 · Mar 31, 2026 $267.3M
Current Assets Q1 2026 · Dec 31, 2025 $260.94M
Total Assets Q1 2026 · Mar 31, 2026 $350.63M
Total Assets Q1 2026 · Dec 31, 2025 $340.05M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.10
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$3.54
Eps Basic Q1 2026 · Mar 31, 2026 −$1.10
Eps Basic restated Q1 2026 · Mar 31, 2025 −$3.54
Sga Expense Q1 2026 · Mar 31, 2026 $9.56M
Sga Expense Q1 2026 · Mar 31, 2025 $14.05M
Rd Expense Q1 2026 · Mar 31, 2026 $36.6M
Rd Expense Q1 2026 · Mar 31, 2025 $43.45M
Net Income Q1 2026 · Mar 31, 2026 −$24.15M
Net Income Q1 2026 · Mar 31, 2025 −$52.2M
Operating Income Q1 2026 · Mar 31, 2026 −$44.26M
Operating Income Q1 2026 · Mar 31, 2025 −$57.37M
Revenue Q1 2026 · Mar 31, 2026 $2K
Revenue Q1 2026 · Mar 31, 2025 $7K